🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — my results so far Page 3

CagriSema (amylin + semaglutide) — my results so far

Dr.NutriCornell Wed, Apr 1, 2026 at 9:59 AM 31 replies 1,170 viewsPage 3 of 7
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Apr 1, 2026 at 7:18 PM#11
MASHdoc_SA said:
Steady state is the thing most people miss.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Apr 1, 2026 at 11:18 PM
44 19FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 41 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Apr 1, 2026 at 10:25 PM#12
Dr.EndoEP said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

This answered a question I did not know how to ask. I will report back once I have actually tried it.

Last edited: Apr 2, 2026 at 12:25 AM
43 18TinaHashiRN, robert_kc, dan_philly and 40 others
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Apr 2, 2026 at 1:32 AM#13
MASHdoc_SA said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: Apr 2, 2026 at 6:32 AM
42 17rachel_ABQ, traveltech_sara, AttorneyGrant and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Apr 2, 2026 at 4:39 AM#14

Adding the numbers, since they settle part of this. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

41 16emily_PDX, Dr.SleepRoch, laura_annarbor and 38 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 2, 2026 at 7:46 AM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.

Last edited: Apr 2, 2026 at 9:46 AM
40 15PurityPaulOR, MaxMetOK, MounjBrad and 37 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register